- Home
- USIO vs PSTV Comparison
USIO vs PSTV Comparison
Compare USIO & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | PSTV |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 27.9M |
| IPO Year | 1999 | 2016 |
Fundamental Metrics
Financial Performance| Metric | USIO | PSTV |
|---|---|---|
| Price | $1.19 | $6.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $55.00 |
| AVG Volume (30 Days) | 22.3K | ★ 2.9M |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,200,535.00 | $5,213,000.00 |
| Revenue This Year | $12.15 | $13.20 |
| Revenue Next Year | $8.57 | $261.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $0.13 |
| 52 Week High | $2.02 | $8.00 |
Technical Indicators
Market Signals| Indicator | USIO | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 73.18 |
| Support Level | $1.03 | $0.37 |
| Resistance Level | $1.42 | N/A |
| Average True Range (ATR) | 0.05 | 0.82 |
| MACD | 0.01 | 0.19 |
| Stochastic Oscillator | 41.67 | 71.18 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).